CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2019—A new CAP Q-Probes benchmarking study on expression rates in invasive breast carcinoma will be available beginning in June.
The study, developed by the CAP Quality Practices Committee, is appropriate for anatomic pathology departments and laboratories that perform or interpret breast predictive markers, or do both. It will make it possible for them to compare the percentage of invasive breast cancer cases positive for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, or HER2, with those of other laboratories.
The study will be available through August. The results will help laboratories address CAP Laboratory Accreditation Program checklist requirement ANP.22970, which says that for IHC and ISH tests performed on breast carcinoma that provide independent predictive information, the laboratory at least annually compares its patient results with published benchmarks and evaluates interobserver variability among the pathologists in the laboratory.